Suzanne L. Bruhn, Ph.D.

Suzanne L. Bruhn, Ph.D. has served as a director of Travere Therapeutics since April 2020. Since November 2023, Dr. Bruhn has served as chief executive officer of The Charcot-Marie-Tooth Association (CMTA), a patient advocacy organization dedicated to finding a cure for CMT, a rare, debilitating peripheral neuropathy. Previously, from May 2019 to December 2023, Dr. Bruhn served as the president and chief executive officer of Tiaki Therapeutics Inc., a biotechnology company. Dr. Bruhn served as president and chief executive officer of Proclara Biosciences, Inc., a biotechnology company, from April 2017 to September 2018, and as president and chief executive officer of Promedior, Inc., a biotechnologycompany, from May 2012 to November 2015. Currently, Dr. Bruhn serves on the boards of directors of Pliant Therapeutics, Inc., Vigil Neuroscience, Inc., and Mind Medicine Inc. (MindMed). Previously, Dr. Bruhn served as a member of the board of directors of Raptor Pharmaceuticals Corp., a pharmaceutical company, from April 2011 until it was acquired by Horizon Pharma plc in October 2016, as a member of the board of directors of Novelion Therapeutics, Inc., a biopharmaceutical company, from October 2017 to January 2020, as a member of the board of directors of Aeglea BioTherapeutics, Inc., a clinical stage biotechnology company, from February 2017 to August 2020, and on the board of directors of Avalo Therapeutics, Inc. (formerly Cerecor, Inc.), a biopharmaceutical company from April 2020 to November 2021. Earlier in her career Dr. Bruhn served in roles of increasing responsibility at Shire Human Genetic Therapies (formerly Transkaryotic Therapies), including senior vice president, strategic planning and program management. Dr. Bruhn received her B.S. degree in chemistry from Iowa State University and her Ph.D. in chemistry from Massachusetts Institute of Technology.